HomeComparePHRRF vs CL

PHRRF vs CL: Dividend Comparison 2026

PHRRF yields 4155.41% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHRRF wins by $10365691035278.93M in total portfolio value
10 years
PHRRF
PHRRF
● Live price
4155.41%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10365691035278.97M
Annual income
$9,897,164,253,693,497,000.00
Full PHRRF calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — PHRRF vs CL

📍 PHRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHRRFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHRRF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHRRF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHRRF
Annual income on $10K today (after 15% tax)
$353,210.06/yr
After 10yr DRIP, annual income (after tax)
$8,412,589,615,639,472,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, PHRRF beats the other by $8,412,589,615,639,467,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHRRF + CL for your $10,000?

PHRRF: 50%CL: 50%
100% CL50/50100% PHRRF
Portfolio after 10yr
$5182845517639.51M
Annual income
$4,948,582,126,846,752,000.00/yr
Blended yield
95.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

PHRRF
No analyst data
Altman Z
-14.2
Piotroski
1/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHRRF buys
0
CL buys
0
No recent congressional trades found for PHRRF or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHRRFCL
Forward yield4155.41%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$10365691035278.97M$41.0K
Annual income after 10y$9,897,164,253,693,497,000.00$5,451.69
Total dividends collected$10333779416010.36M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PHRRF vs CL ($10,000, DRIP)

YearPHRRF PortfolioPHRRF Income/yrCL PortfolioCL Income/yrGap
1← crossover$426,241$415,541.24$11,014$313.84+$415.2KPHRRF
2$17,009,425$16,553,347.24$12,200$415.44+$17.00MPHRRF
3$635,556,863$617,356,778.09$13,607$553.09+$635.54MPHRRF
4$22,238,480,006$21,558,434,161.98$15,301$741.41+$22238.46MPHRRF
5$728,787,067,208$704,991,893,601.52$17,374$1,002.00+$728787.05MPHRRF
6$22,371,952,866,480$21,592,150,704,567.71$19,958$1,367.44+$22371952.85MPHRRF
7$643,400,978,312,961$619,462,988,745,827.60$23,243$1,887.87+$643400978.29MPHRRF
8$17,338,253,847,239,070$16,649,814,800,444,200.00$27,512$2,642.43+$17338253847.21MPHRRF
9$437,875,496,808,855,800$419,323,565,192,309,950.00$33,197$3,759.22+$437875496808.82MPHRRF
10$10,365,691,035,278,973,000$9,897,164,253,693,497,000.00$40,973$5,451.69+$10365691035278.93MPHRRF

PHRRF vs CL: Complete Analysis 2026

PHRRFStock

PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.

Full PHRRF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this PHRRF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHRRF vs SCHDPHRRF vs JEPIPHRRF vs OPHRRF vs KOPHRRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.